ANYGEN Co., Ltd.

Patent Applications and Registrations

Patent applications and USPTO patent grants for ANYGEN Co., Ltd..The latest application filed is for "breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as active ingredient".

Company Profile

1.9.11

ANYGEN Co., Ltd. - Gwangju KR
ANYGEN CO., LTD. - Jeollanam-do KR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Exenatide analogue and use thereof Grant 11,103,557 - Kim , et al. August 31, 2	2021-08-31
Breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as active ingredient Grant 10,285,979 - Kim , et al.	2019-05-14
Breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as active ingredient App 20180147182 - KIM; Jae il ; et al.	2018-05-31
Transmucosal Delivery Of Pharmaceutical Active Substances App 20170252453 - JON; Sangyong ; et al.	2017-09-07
Novel Exenatide Analogue And Use Thereof App 20170128541 - KIM; Jae Il ; et al.	2017-05-11
Method for regulating circadian rhythms Grant 9,556,242 - Seong , et al. January 31, 2	2017-01-31
Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors Grant 8,859,783 - Kim , et al. October 14, 2	2014-10-14
Transmucosal Delivery Of Pharmaceutical Active Substances App 20140256623 - JON; Sangyong ; et al.	2014-09-11
Omega conotoxins Grant 8,673,856 - Kim , et al. March 18, 2	2014-03-18
Composition For Regulating Circadian Rhythms, Composition For Diagnosing Circadian Rhythm Disorders And Diagnostic Kit App 20130345141 - Seong; Jae-Young ; et al.	2013-12-26
Indirubin-3'-oxime Derivatives As Potent Cyclin Dependent Kinase Inhibitors App 20120295948 - Kim; Yong-Chul ; et al.	2012-11-22
Potassium channel opener having benzofuroindole skeleton Grant 7,812,177 - Kim , et al. October 12, 2	2010-10-12
Omega Conotoxins App 20100056456 - Kim; Jae Il ; et al.	2010-03-04
Indirubin derivatives having anticancer property against human cancer cell line Grant 7,572,923 - Kim , et al. August 11, 2	2009-08-11
Thermally Crosslinked Contrast Agents App 20090041673 - Jon; Sangyong ; et al.	2009-02-12

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.